As with any medicine, the MHRA will keep the safety of zuranolone under close review.
Similar Posts
Decision: Advertising Investigations: September 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Guidance: MHRA guidance on the use of real-world data in clinical studies to support regulatory decisions
Points to consider when using real-world data in clinical studies
Class 2 Medicines Recall: ChloraPrep 1mL Clear Sterile Solution/Applicator, Becton Dickinson UK Ltd, EL(25)A/36
Becton Dickinson UK Ltd has informed the MHRA that some units exhibit an open seal on the packaging of the applicator. This is linked to the Class 2 Medicines Notification EL(25)A/22. This defect could increase the risk of the applicator device being contaminated with pathogens.
Manufacturer’s Online Reporting Environment (MORE)
A digital platform designed to facilitate the reporting, monitoring, and management of medical device incidents.
MHRA seeks input on AI regulation at ‘pivotal moment’ for healthcare
National Commission is seeking evidence to shape regulation of AI in healthcare and support the UK’s ambition for a world-leading, AI-enabled NHS
Class 4 Medicines Defect Notification: Lexon UK Ltd, Moclobemide 150mg tablets, EL(25)A/50
Lexon UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the cartons for the batches listed in this notification is missing important updated safety information.